Bidiphar

Bidiphar, also known as BIDIPHAR and formally associated with the Vietnamese name Công ty dược Trang Thiết Bị Y Tế Bình Định, is a pharmaceutical and medical-equipment company based in Quy Nhon, Binh Dinh Province, Vietnam. Its business has developed from a provincial state-owned pharmaceutical enterprise into a diversified manufacturer serving Vietnam's domestic healthcare market and selected overseas markets. In addition to pharmaceutical products, the company has produced medical equipment and participated in joint ventures covering infusion therapy, clinical nutrition, generic intravenous medicines, agricultural plantations and mineral-resource activities. The company's predecessor, Nghia Binh Pharmaceutical Enterprise II, was established in 1979. In 1995, it was merged with another state-owned enterprise to create Bidiphar. The business faced severe operating difficulties after the abolition of state provision in 1988. According to the available historical account, pharmaceutical inputs were difficult to obtain, accumulated debt reached VND 250 million, and much of the production equipment had become obsolete. Bidiphar nevertheless adjusted to the changed economic environment, expanded its production scale and diversified its activities. Bidiphar's principal commercial base has remained Vietnam. The company has had 285 products authorized for nationwide distribution, while 70 products were reported to meet export standards. The available reference material identifies exports to six countries and describes the company as relatively successful in Laos and Cambodia, with additional exploration of opportunities in Myanmar. In 2003, Bidiphar was reported to account for approximately one third of Vietnam's pharmaceutical exports, although the total pharmaceutical exports of the country were only about US$2 million at that time. This figure is historical and should not be interpreted as a current measure of the company's size or market share. The company also pursued cross-border investment in southern Laos. In 1994, it became the first company from Binh Dinh Province to cooperate and invest in southern Laos, establishing a joint venture in Champasak Province with a stated investment of US$2 million, of which Bidiphar contributed 80 percent. By 2007, the company was reported to hold approximately 8,000 hectares of plantations in Laos growing rubber, coffee and Oolong tea. A second Lao joint venture was reported by 2010. These activities demonstrate that Bidiphar's historical corporate scope extended beyond healthcare manufacturing, although its pharmaceutical and medical-equipment operations remained its defining business identity. In December 2008, Bidiphar established Fresenius Kabi Bidiphar, a joint venture with Fresenius Kabi. The venture was managed by Fresenius Kabi, headquartered in Ho Chi Minh City and operated production facilities in Quy Nhon. Its product scope included infusion therapy, clinical nutrition and generic intravenous medicines. Bidiphar also established Biotan with a foreign partner for the exploitation of mineral resources in Binh Dinh, including gold. The available material does not provide sufficient current information about ownership changes, financial performance, executive leadership or the present status of every joint venture. Accordingly, Bidiphar is best characterized from the available sources as an active Vietnamese pharmaceutical company with a history of state-enterprise restructuring, export development and diversified joint-venture activity.

Bidiphar's origins date to 1979, when Nghia Binh Pharmaceutical Enterprise II was established. The enterprise operated during a period when pharmaceutical production in Vietnam was strongly influenced by state provision and administrative allocation. In 1988, the removal of state provision created serious challenges for the business. It reportedly faced shortages of production inputs, debt of VND 250 million and obsolete equipment. Rather than closing, the enterprise adapted its operating model, expanded its production capacity and diversified its activities. A major institutional change occurred in 1995, when Nghia Binh Pharmaceutical Enterprise II was merged with another state-owned enterprise. The resulting organization became Bidiphar, associated with the pharmaceutical and medical-equipment activities of Binh Dinh Province. The post-merger company developed a broader manufacturing and distribution base, supplying the Vietnamese market and expanding the number of products authorized for nationwide distribution. Bidiphar also pursued international activity unusually early for a provincial Vietnamese company. In 1994, it established a joint venture in Champasak Province in southern Laos, becoming the first company from Binh Dinh Province to cooperate and invest in that part of Laos. The reported investment was US$2 million, with Bidiphar contributing 80 percent. By 2007, the company was reported to own approximately 8,000 hectares of Lao plantations producing rubber, coffee and Oolong tea. A second joint venture in Laos was reported by 2010. The company's international interests also included exports to six countries and efforts to build business in Laos and Cambodia, with Myanmar identified as a market under consideration. The company's pharmaceutical operations remained its central identity. By the period covered in the available reference material, 285 Bidiphar products had authorization for nationwide distribution in Vietnam, and 70 products were said to comply with export standards. In 2003, Bidiphar reportedly represented around one third of Vietnam's pharmaceutical exports. The national export base was still small at that time, with total Vietnamese pharmaceutical exports stated as approximately US$2 million. Bidiphar expanded its healthcare manufacturing partnerships in December 2008 by creating Fresenius Kabi Bidiphar with Fresenius Kabi. The joint venture was managed by Fresenius Kabi, headquartered in Ho Chi Minh City and manufacturing in Quy Nhon. Its activities covered infusion therapy, clinical nutrition and generic intravenous drugs. This arrangement connected Bidiphar's local production base with an international healthcare company and broadened its presence in hospital-oriented pharmaceutical categories. The company also diversified outside pharmaceuticals through Biotan, a joint venture with a foreign company involved in mineral-resource exploitation in Binh Dinh, including gold. The available sources do not establish the current ownership, operating condition or financial performance of all these ventures. They also do not provide a reliable current executive list or current official website. Bidiphar's documented historical development is therefore characterized by transition from a state-owned predecessor, adaptation to post-1988 market conditions, consolidation in 1995, pharmaceutical and medical-equipment expansion, export development and joint ventures in healthcare, agriculture and natural resources.

• 2010

  Second Laos joint venture reported

  [1]Bidipharen.wikipedia.org

  A second Bidiphar joint venture in Laos was reported.

• 2008

  Fresenius Kabi Bidiphar established

  [1]Bidipharen.wikipedia.org

  Bidiphar and Fresenius Kabi formed a joint venture focused on infusion therapy, clinical nutrition and generic intravenous medicines.

• 2007

  Lao plantation holdings reported

  [1]Bidipharen.wikipedia.org

  Bidiphar was reported to own approximately 8,000 hectares of plantations in Laos producing rubber, coffee and Oolong tea.

• 2003

  Reported contribution to Vietnamese pharmaceutical exports

  [1]Bidipharen.wikipedia.org

  Bidiphar was reported to account for approximately one third of Vietnam's pharmaceutical exports during a period when national pharmaceutical exports totaled about US$2 million.

• 1995

  Bidiphar formed through merger

  [1]Bidipharen.wikipedia.org

  Nghia Binh Pharmaceutical Enterprise II merged with another state-owned enterprise to form Bidiphar.

• 1994

  First southern Laos joint venture

  [1]Bidipharen.wikipedia.org

  Bidiphar established a joint venture in Champasak Province, becoming the first company from Binh Dinh Province to cooperate and invest in southern Laos.

• 1988

  State-provision system abolished

  [1]Bidipharen.wikipedia.org

  The end of state provision created shortages of inputs, debt and obsolete-equipment problems for the predecessor enterprise, prompting operational adaptation.

• 1979

  Predecessor enterprise established

  [1]Bidipharen.wikipedia.org

  Nghia Binh Pharmaceutical Enterprise II, Bidiphar's predecessor, was established.

A Vietnamese pharmaceutical and medical-equipment manufacturer combining domestic healthcare supply with export activity and selected international joint ventures.

• Pharmaceuticals

  Pharmaceutical products

  Bidiphar's core business is the manufacture and distribution of pharmaceutical products for the Vietnamese market and selected export markets. The available reference material states that 285 products were authorized for nationwide distribution in Vietnam and that 70 products met export standards. Specific product names and therapeutic classes are not identified in the source.

• Hospital pharmaceuticals · 2008

  Infusion therapy products

  Infusion therapy products were among the principal outputs of Fresenius Kabi Bidiphar, the joint venture established with Fresenius Kabi in 2008. Production was based in Quy Nhon, while the venture was managed by Fresenius Kabi from Ho Chi Minh City. The available source does not specify individual product names.

• Clinical nutrition · 2008

  Clinical nutrition products

  Clinical nutrition was another product area assigned to Fresenius Kabi Bidiphar. It formed part of the joint venture's hospital-oriented healthcare portfolio alongside infusion therapy and generic intravenous medicines. Detailed formulations and current availability are not provided in the available reference.

• Generic pharmaceuticals · 2008

  Generic intravenous medicines

  Generic intravenous medicines were included in the Fresenius Kabi Bidiphar joint venture's product scope. They represented an extension of Bidiphar's pharmaceutical manufacturing capabilities into injectable and hospital-use medicines. The source does not identify individual active ingredients or brands.

• Medical equipment

  Medical equipment

  Alongside pharmaceuticals, Bidiphar has been described as producing medical equipment. The available material does not provide a detailed catalogue, product families or current manufacturing status for this part of the business.

• 2008

  Formation of Fresenius Kabi BidipharM&A

  Background

  Bidiphar sought to expand its hospital-focused pharmaceutical manufacturing and international cooperation.

  Action taken

  Bidiphar and Fresenius Kabi established a joint venture managed by Fresenius Kabi, with headquarters in Ho Chi Minh City and production in Quy Nhon.

  Aftermath

  The venture covered infusion therapy, clinical nutrition and generic intravenous medicines.

  Source

• 1995

  Consolidation through state-enterprise mergerStrategy

  Background

  The predecessor enterprise had faced shortages, debt and obsolete equipment after the end of state provision. A merger with another state-owned enterprise created Bidiphar.

  Action taken

  The two state-owned enterprises were combined to form Bidiphar.

  Aftermath

  The new company expanded production, diversified its activities and developed a broader domestic and international business base.

  Source

1. 1Bidipharen.wikipedia.org